PEMF: an Adjunct Therapy for Anterior Uveitis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if a medical device (ActiPatch) that emits a low frequency pulsed electromagnetic field (PEMF) will benefit patients with anterior uveitis. Anterior uveitis (aka iritis) is an inflammatory disease involving the front segment of the eye. This is a common cause of a painful red eye, and ActiPatch has been shown to be effective in treating tissue inflammation. The conventional treatment of iritis typically involves frequent administration of topical steroids which have their own inherent risks (development of cataracts and/or glaucoma). The purpose of this study is to determine if ActiPatch therapy can be used to shorten the length of time and/or quantity of steroids administered.

Clinical Trial Description

Iritis is an inflammatory disease focused in the anterior chamber of the eye. The inflammation inside the eye can lead to a number of conditions that ultimately effect vision. These can include glaucoma, posterior synechiae, cystoid macular edema, and cataract. The standard treatment for the disease is drug therapy centered around the administration of corticosteroids. These are administered in the form of eye drops, and if necessary periocular/intraocular injections, or/and by systemic oral/IV administration. Unfortunately, the treatment with corticosteroids can similarly induce severe side effects including glaucoma and cataract formation. ActiPatch is a medical device that emits a low frequency pulsed electromagnetic field. This device has been shown to reduce inflammation and pain in a number of conditions, eg blepharoplasty (eyelid surgery). ActiPatch is FDA approved for use after blepharoplasty to reduce swelling, inflammation and pain. The treatment is not invasive, does not require additional medication, and side effects from ActiPatch and other PEMF devices have not been reported. The potential benefit of treating uveitis with ActiPatch is the potential to reduce the time and/or amount of steroid administration. This would benefit patients by reducing the risk of unwanted side effects of the corticosteroid treatment.

The benefit to society would be an improved treatment for anterior uveitis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01154010
Study type	Interventional
Source	Massachusetts Eye and Ear Infirmary
Contact
Status	Completed
Phase	N/A
Start date	August 2009
Completion date	April 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Recruiting	`NCT01486693` - Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis	N/A
Recruiting	`NCT01156285` - Acute Anterior Uveitis: Psychic Burden and Pain	N/A
Terminated	`NCT00333996` - A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis	Phase 2/Phase 3
Completed	`NCT00405496` - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis	Phase 2
Completed	`NCT02764697` - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients	Phase 4
Completed	`NCT01376362` - Topical Interferon Gamma for Macular Edema Secondary to Uveitis	Phase 1/Phase 2
Recruiting	`NCT00407316` - Quality of Life and Visual Function in Uveitis Patients	Phase 0
Completed	`NCT02725177` - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	N/A
Completed	`NCT01647529` - Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis	N/A
Completed	`NCT00823173` - Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis	Phase 2
Completed	`NCT02517619` - Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis	Phase 3
Completed	`NCT01505088` - Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis	Phase 3
Completed	`NCT02879084` - Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
Completed	`NCT02765308` - Aqueous Humor Dynamics and Hypertensive Uveitis	N/A
Completed	`NCT00130637` - Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis	Phase 2
Completed	`NCT00406887` - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis	Phase 3
Completed	`NCT00876434` - Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PEMF: an Adjunct Therapy for Anterior Uveitis — PEMF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms